TET2 and lymphoma: Several studies have highlighted the characteristic mutational landscape of TFH lymphomas, which typically associates mutations in epigenetic regulators (TET2, DNMT3A, and IDH2), RHOA G17V, and alterations in the T-cell receptor (TCR) signaling pathway [12, 23–26].